Active, not recruitingPhase 3NCT06109779
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
Studying Rare malignant epithelial tumor of liver and intrahepatic biliary tract
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AstraZeneca
- Intervention
- Rilvegostomig(drug)
- Enrollment
- 757 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2030
Study locations (30)
- Research Site, Birmingham, Alabama, United States
- Research Site, Phoenix, Arizona, United States
- Research Site, Los Angeles, California, United States
- Research Site, Orange, California, United States
- Research Site, Stanford, California, United States
- Research Site, Aurora, Colorado, United States
- Research Site, Littleton, Colorado, United States
- Research Site, Washington D.C., District of Columbia, United States
- Research Site, Jacksonville, Florida, United States
- Research Site, Atlanta, Georgia, United States
- Research Site, Chicago, Illinois, United States
- Research Site, Iowa City, Iowa, United States
- Research Site, Kansas City, Kansas, United States
- Research Site, Lexington, Kentucky, United States
- Research Site, New Orleans, Louisiana, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06109779 on ClinicalTrials.govOther trials for Rare malignant epithelial tumor of liver and intrahepatic biliary tract
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06990659Outpatient Versus Inpatient Care Pathway for Intra-arterial Treatment of Primary Liver Cancer (CHOC)University Hospital, Angers
- RECRUITINGPHASE2NCT07146646Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract CancerCase Comprehensive Cancer Center
- RECRUITINGPHASE2NCT06529718Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer PatientsUNICANCER
- RECRUITINGNCT07151118ctDNA in Genetic Profiling and Clinical Outcomes of Advanced Biliary Tract CancerCHA University
- RECRUITINGNCT07142226Role of ctDNA in Genetic Profiling & Outcomes for Advanced BTCCHA University
- RECRUITINGPHASE2NCT07135544A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract CancerYongjun Chen
- RECRUITINGNCT06793709A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After ChemotherapyEisai Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT06708663HX009+ IN10018 with or Without Standard Chemotherapy for Advanced Solid TumoursHangzhou Hanx Biopharmaceuticals, Ltd.
See all trials for Rare malignant epithelial tumor of liver and intrahepatic biliary tract →